Edmund Harrigan
CIK 1177917 · last filed 2026-10-02
Edmund Harrigan is a corporate insider who has filed 66 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing shows the insider was granted $25.0K of INCY on Oct 2, 2026. Across all open-market trades the lifetime net is −$4.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.5M across reported positions. 36 SEC filings were submitted jointly with INCYTE CORP.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Director | 23,225 | $115.52 | $2.68M | $0 | 36 | 2026-10-02 |
| ACAD | Director | 43,148 | $19.72 | $850.9K | $33.0K | 14 | 2026-06-01 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Director | 6,000 | $0.07 | $421 | $24.7K | 6 | 2022-05-20 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 55,163 | $329.83 | $18.19M | -$4.52M | 6 | 2020-08-14 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | Director | — | $0.07 | — | $0 | 3 | 2019-06-14 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-02 | INCY | Grant (A) | +206 | $25.0K | EDGAR |
| 2026-07-02 | INCY | Grant (A) | +255 | $28.9K | EDGAR |
| 2026-06-10 | INCY | Grant (A) | +1,642 | $0 | EDGAR |
| 2026-06-01 | ACAD | Mixed | +8,107 | $0 | EDGAR |
| 2026-04-02 | INCY | Grant (A) | +269 | $25.3K | EDGAR |
| 2026-01-05 | INCY | Grant (A) | +245 | $24.2K | EDGAR |
| 2025-10-02 | INCY | Grant (A) | +289 | $24.5K | EDGAR |
| 2025-07-02 | INCY | Grant (A) | +367 | $25.0K | EDGAR |
| 2025-06-12 | INCY | Grant (A) | +2,518 | $0 | EDGAR |
| 2025-06-02 | ACAD | Mixed | +9,387 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.